| Trial ID: | L0607 |
| Source ID: | JPRN-UMIN000018166
|
| Associated Drug: |
SGLT2 inhibitor
|
| Title: |
Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease. - SGLT2 inhibitor for diabetes complicated by NAFLD.
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Type 2 diabetes complicated by non-alcoholic fatty liver disease
|
| Interventions: |
SGLT2 inhibitor is administered orally for 24 weeks or more.
|
| Outcome Measures: |
Histologial changes of liver and safety of treament are evaluated at two points of the baseline and 24 weeks after the start of treatment.Fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, and body composition are evaluated at two points of the baseline and 24 weeks after the start of treatment.
|
| Sponsor/Collaborators: |
Toranomon Hospital, Department of Hepatology
|
| Gender: |
All
|
| Age: |
20years-old64years-old
|
| Phases: |
Not selected
|
| Enrollment: |
15
|
| Study Type: |
Interventional
|
| Study Designs: |
Single arm Non-randomized
|
| Start Date: |
02/07/2015
|
| Completion Date: |
31/03/2025
|
| Results First Posted: |
--
|
| Last Update Posted: |
13 July 2020
|
| Locations: |
Japan
|
| URL: |
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021037
|
